<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185039</url>
  </required_header>
  <id_info>
    <org_study_id>MMP-Rein-IPC 2015-029</org_study_id>
    <nct_id>NCT03185039</nct_id>
  </id_info>
  <brief_title>Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents</brief_title>
  <official_title>Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic (Localized Kidney Cancer and Oligometastatic)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in
      metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or
      Pazopanib).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to analyze the predictive impact of circulating MMP2 and MMP9 on the
      progression-free survival of patients with metastatic kidney cancer treated with
      anti-angiogenic agents (Sunitinib or Pazopanib) in comparison with two untreated cohorts
      (localized or oligometastatic cancer).

      Prospective monocenter, open-label study

      In the frame of disease management blood samples will be collected at different times of
      follow-up regarding disease status (localized, oligometastatic and metastatic) and tissue
      samples will be collected for patients scheduled for surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">November 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma level of the MMP2 and MMP9 markers</measure>
    <time_frame>at initial sampling</time_frame>
    <description>ELISA assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival without progression</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>date of progression (RECIST criteria), date of death</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>kidney cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Localized, oligometastatic or metastatic</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood and tumor samples</intervention_name>
    <description>Blood and tumor samples</description>
    <arm_group_label>kidney cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient male or female, aged of more than 18 years

          2. Patient with any of the following conditions:

               -  Kidney cancer localized at diagnosis.

               -  Metastatic kidney cancer when anti-angiogenic therapy is initiated by Sunitinib
                  or Pazopanib

               -  Oligometastatic kidney cancer without systemic treatment (local treatment)

          3. ECOG = 0 to 2

          4. Patient affiliated to, or beneficiary of, the national social security.

          5. Patient having signed informed consent

        Exclusion Criteria:

          1. Patient previously treated with anti-angiogenic agents.

          2. Person in an emergency situation, adult subject to a legal protection measure (a
             guardian, guardianship or safeguard of justice), or unable of expressing his / her
             consent.

          3. Impossibility to undergo the medical follow-up of the trial for geographical, social
             or psychological reasons 4. History of malignant disease in the 5 years prior to
             inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in
             situ, or prostate cancer with a good prognosis (stage T &lt;3 and Gleason &lt;7))
             accidentally discovered during the histological analysis of the tumor sample.

        5- Pregnant or nursing women 6- Contraindications to the procedure of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle BOQUET, PhD</last_name>
    <phone>+33 4 91 22 37 78</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GENRE Dominique, MD</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Boquet, PhD</last_name>
      <phone>33 (0)4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GRAVIS Gwénaëlle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://institutpaolicalmettes.fr</url>
    <description>Official website of the sponsor</description>
  </link>
  <results_reference>
    <citation>Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1. Review.</citation>
    <PMID>21126687</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014 Mar;16(3):392-9. doi: 10.1093/neuonc/not226. Epub 2013 Dec 9.</citation>
    <PMID>24327581</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabouret E, Boudouresque F, Farina P, Barrié M, Bequet C, Sanson M, Chinot O. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol. 2015 Aug;17(8):1174-6. doi: 10.1093/neuonc/nov094.</citation>
    <PMID>26142442</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.</citation>
    <PMID>26921265</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

